Cargando…

Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia

OBJECTIVE: To elucidate the degree of genetic polymorphisms CYP2C19 (CYP2C19*2, CYP2C19*3) of key drug metabolizing enzymes on the antiplatelet effect of clopidogrel response in patients with acute ischemic stroke from Saudi Arabia. METHODS: A case-control study carried out at Neurology Clinics at A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhazzani, Adel A., Munisamy, Murali, Karunakaran, Gauthaman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Riyadh : Armed Forces Hospital 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726834/ https://www.ncbi.nlm.nih.gov/pubmed/28064328 http://dx.doi.org/10.17712/nsj.2017.1.20160303

Ejemplares similares

Pharmacogenetics of CYP3A5 on Carbamazepine pharmacokinetics in epileptic patients developing toxicity
por: Al-Gahtany, Mubarak, et al.
Publicado: (2014)

Pharmacogenetics of uridine diphosphate glucuronosyltransferase (UGT2B7) genetic polymorphism on valproic acid pharmacokinetics in epilepsy
por: Munisamy, Murali, et al.
Publicado: (2014)

Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review
por: Alhazzani, Adel, et al.
Publicado: (2021)

Preference and Values of Stroke Interventions, Kingdom of Saudi Arabia
por: Alamri, Reem, et al.
Publicado: (2019)

Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients
por: Li, Changqing, et al.
Publicado: (2021)

The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention
por: Liu, Guohua, et al.
Publicado: (2020)

Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China
por: Chang, Rong, et al.
Publicado: (2022)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel
por: Nassar, Suheir, et al.
Publicado: (2014)

Study of Stroke Incidence in the Aseer Region, Southwestern Saudi Arabia
por: Alhazzani, Adel A., et al.
Publicado: (2018)

Protected Stroke Mechanical Thrombectomy Code During the Coronavirus (COVID-19) Pandemic: Southwestern Part of Saudi Arabia Stroke Unit Local Protocol
por: Alqahtani, Saeed A, et al.
Publicado: (2020)

In Hospital Stroke Mortality: Rates and Determinants in Southwestern Saudi Arabia
por: Alhazzani, Adel A., et al.
Publicado: (2018)

Risk Factors of the First-Time Stroke in the Southwest of Saudi Arabia: A Case-Control Study
por: Alhazzani, Adel A., et al.
Publicado: (2021)

A Pharmacogenetic Study of CYP2C19 in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy
por: Angulo-Aguado, Mariana, et al.
Publicado: (2021)

Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions
por: Saab, Yolande B, et al.
Publicado: (2015)

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt
por: Shawky, Ahmed, et al.
Publicado: (2023)

Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy
por: Alvitigala, Bhawani Yasassri, et al.
Publicado: (2020)

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”
por: Wang, Bin, et al.
Publicado: (2018)

Awareness of stroke among patients attending primary healthcare services in Abha, Southwestern Saudi Arabia
por: Alhazzani, Adel A., et al.
Publicado: (2019)

Cardioprotective role of methanolic extract of bark of Terminalia arjuna against in-vitro model of myocardial ischemic-reperfusion injury
por: Karunakaran, Gauthaman
Publicado: (2015)

The impact of CYP2C19 *2 and *3 polymorphism on clopidogrel response following coronary stenting in Saudi patients with acute coronary syndrome
por: H, Khalaf, et al.
Publicado: (2014)

Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics
por: Dahl, Marja-Liisa, et al.
Publicado: (2010)

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
por: Amin, Arwa M., et al.
Publicado: (2017)

Demographic characteristics and types of stroke in Southwestern Saudi Arabia, and the potential demand of neuro endovascular specialists
por: Alnaami, Ibrahim, et al.
Publicado: (2021)

Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis
por: Yao, Jia-Chen, et al.
Publicado: (2018)

Investigating Real‐World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records
por: Tornio, Aleksi, et al.
Publicado: (2017)

Withdrawal of two generic clopidogrel products in Saudi Arabia for non-bio-equivalence
por: Alsultan, Abdullah Saleh, et al.
Publicado: (2018)

The clinical impact of CYP2C19 *2 and *3 polymorphism on Clopidogrel and cost analysis
por: Meman A, Al, et al.
Publicado: (2014)

Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availability: Application: Pharmacogenomics
por: Ned, Renée M.
Publicado: (2010)

Variants in clopidogrel-relevant genes and early neurological deterioration in ischemic stroke patients receiving clopidogrel
por: Yi, Xingyang, et al.
Publicado: (2020)

Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke
por: Rath, Charlotte Lützhøft, et al.
Publicado: (2020)

Public Awareness of Ischemic Stroke in Medina city, Kingdom of Saudi Arabia
por: Alluqmani, Majed M., et al.
Publicado: (2021)

Pharmacogenetic Selection of Volunteers Increases Stringency of Bioequivalence Studies; The Case of Clopidogrel
por: Garcés-Eisele, J., et al.
Publicado: (2014)

The use of oral suspension and rationally prescribing alternatives may be supplemental to the implementation of clopidogrel new algorithm comprising CYP2C19 pharmacogenetics and drug interactions
por: Chen, Meng, et al.
Publicado: (2016)

Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China
por: Su, Qiang, et al.
Publicado: (2019)

The Common Neurological Presentations and Clinical Outcomes of Coronavirus Disease 2019 in Saudi Arabia
por: Alkeridy, Walid A., et al.
Publicado: (2021)

The association of diabetes with ischemic stroke and transient ischemic attacks in a tertiary center in Saudi Arabia
por: Homoud, Bareen, et al.
Publicado: (2020)

Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke
por: Yi, Xingyang, et al.
Publicado: (2016)

Knowledge, perception, and confidence of hospital pharmacists toward pharmacogenetics in Jeddah, Kingdom of Saudi Arabia
por: Bagher, Amina M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_go1ravfe8e1oh9ep35eg7cf4ig